Manufacturer's investigation conclusion: a direct correlation between heartmate ii left ventricular assist system (lvas), serial number (b)(6), and the reported embolic stroke, hemorrhagic stroke, ventricular tachycardia, and patient outcome could not conclusively be established through this evaluation.Heartmate ii lvas, serial (b)(6), was not explanted.The submitted log file contained data from 16:08:55 on (b)(6) 2021 to 00:07:24 on (b)(6) 2021.Three transient low flow events were captured at 23:24:53, 23:25:46, and 23:26:25 on (b)(6) 2021 when calculated flow decreased to below the low flow threshold.The account attributed these events to ventricular tachycardia.Additionally, no external power events that the account attributed to the patient simultaneously unplugging both power cables were recorded in the log file.The device appeared to be operating as intended at the set speed.The relevant sections of the device history records for (b)(6) were reviewed and showed no deviations from manufacturing or quality assurance specifications.The heartmate ii left ventricular assist system (lvas) instructions for use (ifu) is currently available.Section 1 of this ifu lists stroke, bleeding, cardiac arrhythmia, and death as adverse events that may be associated with the use of the heartmate ii lvas.Section 6 outlines the recommended anticoagulation therapy and international normalized ratio (inr) range.No further information was provided.The manufacturer is closing the file on this event.
|